Combination of pegylated liposomal doxorubicin (PLD) and paclitaxel in patients with advanced soft tissue sarcoma: a phase II study of the Hellenic Cooperative Oncology Group

D Bafaloukos, C Papadimitriou, H Linardou, G Aravantinos, P Papakostas, D Skarlos, P Kosmidis, G Fountzilas, H Gogas, C Kalofonos, A M Dimopoulos, D Bafaloukos, C Papadimitriou, H Linardou, G Aravantinos, P Papakostas, D Skarlos, P Kosmidis, G Fountzilas, H Gogas, C Kalofonos, A M Dimopoulos

Abstract

Patients with soft tissue sarcoma (STS), even after complete local disease control, often relapse locally or with distant metastases. This multicenter phase II study was conducted to evaluate the safety and efficacy of the combination of pegylated liposomal doxorubicin (PLD) and paclitaxel, as first-line treatment in patients with advanced STS. In all, 42 patients with locally advanced or metastatic STS, median age 54 years and median Eastern Cooperative Oncology Group performance status (PS) 1 were treated with PLD 45 mg m(-2) and paclitaxel 150 mg m(-2), every 28 days for a total of six cycles. Histological types included mainly leiomyosarcomas (43%), malignant fibrous histiocytomas (14%) and liposarcomas (12%). At study entry, 69% of patients had distant metastases. Overall response rate was 16%, including one complete (CR 2%) and six partial responses (PRs 14%), while an additional 14 patients had disease stabilization (SD 33%). At median follow-up 41.5 months, median time to progression (TTP) was 5.7 months with median overall survival (OS) 13.2 months. Grade 3-4 toxicities included neutropenia (17%), anaemia (15%), neurotoxicity (5%) and palmar-plantar erythrodysesthesia (9%). There were no treatment-related deaths. The combination of PLD and paclitaxel is a safe and well-tolerated regimen demonstrating modest efficacy as first-line treatment in patients with advanced STS.

Figures

Figure 1
Figure 1
Time to progression (- - - -) and OS (—) of 42 patients with advanced STS treated with PLD/paclitaxel combination. Median Follow-up: 41.5 months, median survival: 13.2 months, events/total: 36/42, median TTP: 5.7 months.

References

    1. Antman KH, Elias A, Ryan L (1990) Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules. Semin Oncol 17(Suppl 4): 68–73
    1. Balcerzak SP, Benedetti J, Weiss GR, Natale RB (1995) A phase II trial of paclitaxel in patients with advanced soft tissue sarcomas. A Southwest Oncology Group study. Cancer 76: 2248–2252
    1. Benjamin RS (1987) Grade 3 nausea, vomiting and myelosuppression or progressive, metastatic sarcoma? J Clin Oncol 5: 833–835
    1. Briasoulis E, Tzamakou E, Rammou D (1999) Phase I trial and interaction pharmacokinetics of PEG-liposomal doxorubicin and weekly taxol. Br J Cancer 80(Suppl 2): 63–66
    1. Casper ES, Schwartz GK, Sugarman A, Leung D, Brennan MF (1997) Phase I trial of dose-intense liposome-encapsulated doxorubicin in patients with advanced sarcoma. J Clin Oncol 15: 211–2117
    1. Casper ES, Waltzman RJ, Schwartz GK, Sugarman A, Pfister D, Ilson D, Woodruff J, Leung D, Bertino JR (1998) Phase II trial of paclitaxel in patients with soft tissue sarcoma. Cancer Invest 16: 442–446
    1. Chidiac T, Budd GT, Pelley R, Sandstrom K, McLain D, Elson P, Crownover R, Marks K, Muschler G, Joyce M, Zehr R, Bukowski R (2000) Phase II trial of liposomal doxorubicin (Doxil) in advanced soft tissue sarcomas. Invest New Drugs 18: 253–259
    1. De Pas T, De Braud F, Orlando L, Nole F, Munzone E, Zampino MG, Fazio N, Aapro MS, Goldhirsch A (1998) High-dose ifosfamide plus adriamycin in the treatment of adult advanced soft tissue sarcomas: is it feasible? Ann Oncol 9: 917–919
    1. Dirix LY, van Oosterom AT (1999) Soft tissue sarcoma in adults. Curr Opin Oncol 11: 285–295
    1. Edmonson JH, Ryan LM, Blum RH, Brooks JS, Shiraki M, Frytak S, Parkinson DR (1993) Randomised comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol 11: 1269–1275
    1. Fata F, O'Reilly E, Ilson D, Pfister D, Leffel D, Kelsen DP, Schwartz GK, Casper ES (1999) Paclitaxel in the treatment of patients with angiosarcoma of the scalp or face. Cancer 86: 2034–2037
    1. Gabizon A, Isacson R, Libson E, Kaufman B, Uziely B, Catane R, Ben-Dor CG, Rabello E, Cass Y, Peretz T (1994) Clinical studies of liposome-encapsulated doxorubicin. Acta Oncol 33: 779–786
    1. Gianni L, Munzone E, Capri G, Fulfaro F, Tarenzi E, Villani F, Spreafico C, Laffranchi A, Caraceni A, Martini C (1995) Paclitaxel by 3-hour infusion in combination with bolus doxorubicin in women with untreated metastatic breast cancer: high antitumour efficacy and cardiac effects in a dose-finding and sequence-finding study. J Clin Oncol 13: 2688–2699
    1. Gogas H, Papadimitriou C, Kalofonos HP, Bafaloukos D, Fountzilas G, Tsavdaridis D, Anagnostopoulos A, Onyenadum A, Papakostas P, Economopoulos T, Christodoulou C, Kosmidis P, Markopoulos C (2002) Neoadjuvant chemotherapy with a combination of pegylated liposomal doxorubicin (Caelyx) and paclitaxel in locally advanced breast cancer: a phase II study by the Hellenic Cooperative Oncology Group. Ann Oncol 13: 1737–1742
    1. Judson I, Radford JA, Harris M, Blay JY, van Hoesel Q, le Cesne A, van Oosterom AT, Clemons MJ, Kamby C, Hermans C, Whittaker J, Donato di Paola E, Verweij J, Nielsen S (2001) Randomised phase II trial of pegylated liposomal doxorubicin in the treatment of advanced or metastatic soft tissue sarcoma: a study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer 37: 870–877
    1. Kaplan E, Meier P (1958) Nonparametric estimation from incomplete observations. J Am Stat Assoc 53: 457–481
    1. Kostler WJ, Brodowicz T, Attems Y, Hejna M, Tomek S, Amann G, Fiebiger WC, Wiltschke CH, Krainer M, Zielinski CC (2001) Docetaxel as rescue medication in anthracycline- and ifosfamide-resistant locally advanced or metastatic soft tissue sarcoma: results of a phase II trial. Ann Oncol 12: 1281–1288
    1. Lasic D (1996) Doxorubicin in sterically stabilised liposomes. Nature 380: 561–562
    1. Lyass O, Uziely B, Ben-Yosef R, Tzemach D, Heshing NI, Lotem M, Brufman G, Gabizon A (2000) Correlation of toxicity with pharmacokinetics of pegylated liposomal doxorubicin (Doxil). Cancer 89: 1037–1047
    1. Mavroudis D, Kouroussis CH, Kakolyris S, Agelaki S, Kalbakis K, Androulakis N, Souglakos J, Samonis G, Georgoulias V (2002) Phase I study of paclitaxel (taxol) and pegylated liposomal doxorubicin (caelyx) administered every 2 weeks in patients with advanced solid tumours. Oncology 62: 216–222
    1. O'Bryan RM, Baker LH, Gottlieb JE, Rivkin SE, Balcerzak SP, Grumet GN, Salmon SE, Moon TE, Hoogstraten B (1977) Dose response evaluation of adriamycin in human neoplasia. Cancer 39: 1940–1948
    1. Patel SR, Vadhan-Raj S, Burgess MA, Plager C, Papadopolous N, Jenkins J, Benjamin RS (1998) Results of two consecutive trials of dose-intensive chemotherapy with doxorubicin and ifosfamide in patients with sarcomas. Am J Clin Oncol 21: 317–321
    1. Pinedo HM, Kenis Y (1977) Chemotherapy of advanced soft-tissue sarcomas in adults. Cancer Treat Rev 4: 67–86
    1. Pivot X, Chevreau C, Cupissol D, Lortholary A, Bui NB, Eymard JC, Bay JO, Baranzelli MC, Mita M, Barnouin L, Savary J, Thyss A (2002) Phase II trial of Paclitaxel–Epirubicin in patients with recurrent soft tissue sarcoma. Am J Clin Oncol 25: 561–564
    1. Sandler A, Fox S, Meyers T, Rougraff B (1998) Paclitaxel (taxol) plus doxorubicin plus filgrastim in advanced sarcoma: a phase II study. Am J Clin Oncol 21: 241–245
    1. Santoro A (1999) Advanced soft tissue sarcoma: how many more trials with anthracyclines and ifosfamide? Ann Oncol 10: 151–154
    1. Santoro A, Tursz T, Mouridsen H, Verweij J, Steward W, Somers R, Buesa J, Casali P, Spooner D, Rankin E (1995) Doxorubicin versus CYVADIC versus doxorubicin plus ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomised study of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 13: 1537–1545
    1. Sarcoma Meta-analysis Collaboration (1997) Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Lancet 350: 1647–1654
    1. Spira AI, Ettinger DS (2002) The use of chemotherapy in soft tissue sarcomas. Oncologist 7: 348–359
    1. Steward WP, Verweij J, Somers R, Spooner D, Kerbrat P, Clavel M, Crowther D, Rouesse J, Tursz T, Tueni E (1993) Granulocyte-macrophage colony-stimulating factor allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue sarcomas: a study of the European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol 11: 15–21
    1. Stewart S, Harrington KJ (1997) The biodistribution and pharmacokinetics of stealth liposomes in patients with solid tumours. Oncology 11(Suppl 11): 33–37
    1. Toma S, Tucci A, Villani G, Carteni G, Spadini N, Palumbo R (2000) Liposomal doxorubicin (Caelyx) in advanced pretreated soft tissue sarcomas: a phase II study of the Italian Sarcoma Group (ISG). Anticancer Res 20: 485–491
    1. Uziely B, Jeffers S, Isacson R, Kutsch K, Wei-Tsao D, Yehoshua Z, Libson E, Muggia FM, Gabizon A (1995) Liposomal doxorubicin: antitunour activity and unique toxicities during two complementary phase I studies. J Clin Oncol 13: 1777–1785
    1. van Glabbeke M, van Oosterom AT, Oosterhuis JW, Mouridsen H, Crowther D, Somers R, Verweij J, Santoro A, Buesa J, Tursz T (1999) Prognostic factors for the outcome of chemotherapy in advanced soft tissue sarcoma: an analysis of 2,185 patients treated with anthacycline-containing first-line regimens – a European Organization for the Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group study. J Clin Oncol 17: 150–158
    1. van Hoesel QG, Verweij J, Catimel G, Clavel M, Kerbrat P, van Oosterom AT, Kerger J, Tursz T, van Glabbeke M, van Pottelsberghe C, Ledril N, Mouridsen H (1994) Phase II study with docetaxel (Taxotere) in advanced soft tissue sarcomas of the adult. EORTC Soft Tissue and Bone Sarcoma Group. Ann Oncol 5: 539–542

Source: PubMed

Sponzoři a spolupracovníci

Zdravotní podmínky

Drogové intervence

3
Předplatit